Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders.

For further information, please contact:

Julie Silber, Director IR and Communications
Tel: 046-540 82 03